Cancer Research and Treatment

Original Articles

Predictive Factors for Radiation Pneumonitis in Lung Cancer Treated with Helical Tomotherapy: Youngkyong Kim, Seong Eon Hong, Moonkyoo Kong, Jinhyun Choi; Cancer Res Treat. 2013;45(4):295-302. Published online December 31, 2013; DOI: https://doi.org/10.4143/crt.2013.45.4.295

PURPOSE
Predictive factors for radiation pneumonitis (RP) after helical tomotherapy (HT) may differ from those after linac-based radiotherapy. In this study, we identified predictive factors for RP in patients with lung cancer treated with HT.
MATERIALS AND METHODS
We retrospectively analyzed clinical, treatment-related and dosimetric factors from 31 patients with lung cancer treated with HT. RP was graded according to Common Terminology Criteria for Adverse Events version 4.0 and grade > or =2 RP was defined as a RP event. We used Kaplan-Meier methods to compute the actuarial incidence of RP. For univariate and multivariate analysis, the log-rank test and the Cox proportional regression hazard model were used. We generated receiver-operating characteristics (ROC) curves to define the cutoff values for significant parameters.
RESULTS
The median follow-up duration was 6.6 months (range, 1.6 to 38.5 months). The 2-, 4-, and 6-month actuarial RP event rates were 13.2%, 58.5%, and 67.0%, respectively. There was no grade 4 or more RP. Ipsilateral V5, V10, V15, and contralateral V5 were related with RP event on univariate analysis. By multivariate analysis, ipsilateral V10 was factor most strongly associated with RP event. On the ROC curve, the cutoff values of ipsilateral V5, V10, V15, and contralateral V5 were 67.5%, 58.5%, 50.0%, and 55.5%, respectively.
CONCLUSION
In our study, ipsilateral V5, V10, V15, and contralateral V5 were significant predictive factors for RP after HT.

Citations

Citations to this article as recorded by

Predictive factors for severe radiation-induced lung injury in patients with lung cancer and coexisting interstitial lung disease
Shin-Hyung Park, Jae-Kwang Lim, Min Kyu Kang, Jongmoo Park, Chae Moon Hong, Chang Ho Kim, Seung Ick Cha, Jaehee Lee, Seoung-Jun Lee, Jae-Chul Kim
Radiotherapy and Oncology.2024; 192: 110053. CrossRef
Deep-Learning Model Prediction of Radiation Pneumonitis Using Pretreatment Chest Computed Tomography and Clinical Factors
Jang Hyung Lee, Min Kyu Kang, Jongmoo Park, Seoung-Jun Lee, Jae-Chul Kim, Shin-Hyung Park
Technology in Cancer Research & Treatment.2024;[Epub] CrossRef
Pulmonary toxicity of craniospinal irradiation using helical tomotherapy
Joongyo Lee, Euidam Kim, Nalee Kim, Chang-Ok Suh, Yoonsun Chung, Hong In Yoon
Scientific Reports.2022;[Epub] CrossRef
Comparison of Radiation Pneumonitis in Lung Cancer Patients Treated with HT versus IMRT and Circulating Lymphocyte Subsets as Predicting Risk Factors
Xin Zhang, Dingyi Yang, Yong Jiang, Luo Huang, Can Wang, Dan Tao, Xianfeng Liu, Yongyang Lei, Yongzhong Wu, Wei Zhou
Journal of Inflammation Research.2021; Volume 14: 4205. CrossRef
The Efficacy and Safety of Acupuncture for Preventing Radiation Pneumonitis in Patients With Lung Cancer: A Prospective, Single-Blinded, Randomized Pilot Proof-of-Principle Study
Moonkyoo Kong, Seung Hyeun Lee, Jaehyo Kim, Beom-Joon Lee, Kwan-Il Kim
Integrative Cancer Therapies.2020;[Epub] CrossRef
Phase II study of compensator-based non-coplanar intensity-modulated radiotherapy for Stage I non–small-cell lung cancer
Tomohiro Itonaga, Ryuji Mikami, Hidetsugu Nakayama, Tatsuhiko Saito, Sachika Shiraishi, Mitsuru Okubo, Shinji Sugahara, Norihiko Ikeda, Koichi Tokuuye
Journal of Radiation Research.2019; 60(3): 387. CrossRef
Dosimetric Comparison Between Jaw Tracking and No Jaw Tracking in Intensity-Modulated Radiation Therapy
Shengyu Yao, Yin Zhang, Tingfeng Chen, Guoqi Zhao, Zhekai Hu, Xiaokai Lu, Yong Liu
Technology in Cancer Research & Treatment.2019;[Epub] CrossRef
A new Monte Carlo model of a Cyberknife® system for the precise determination of out-of-field doses
J Colnot, V Barraux, C Loiseau, P Berejny, A Batalla, R Gschwind, C Huet
Physics in Medicine & Biology.2019; 64(19): 195008. CrossRef
Treatment outcomes and patterns of radiologic appearance after hypofractionated image-guided radiotherapy delivered with helical tomotherapy (HHT) for lung tumours
Stefano Arcangeli, Lorenzo Falcinelli, Stefano Bracci, Alessandro Greco, Alessia Monaco, Jessica Dognini, Cinzia Chiostrini, Rita Bellavita, Cynthia Aristei, Vittorio Donato
The British Journal of Radiology.2017;[Epub] CrossRef
Patterns of CT lung injury and toxicity after stereotactic radiotherapy delivered with helical tomotherapy in early stage medically inoperable NSCLC
S Arcangeli, L Agolli, L Portalone, M R Migliorino, M G Lopergolo, A Monaco, J Dognini, M C Pressello, S Bracci, V Donato
The British Journal of Radiology.2015; 88(1048): 20140728. CrossRef
Early Toxicity in Patients Treated With Postoperative Proton Therapy for Locally Advanced Breast Cancer
John J. Cuaron, Brian Chon, Henry Tsai, Anuj Goenka, David DeBlois, Alice Ho, Simon Powell, Eugen Hug, Oren Cahlon
International Journal of Radiation Oncology*Biology*Physics.2015; 92(2): 284. CrossRef
Risk of radiation-induced pneumonitis after helical and static-port tomotherapy in lung cancer patients and experimental rats
Xianglan Zhang, You Keun Shin, Zhenlong Zheng, Lianhua Zhu, Ik Jae Lee
Radiation Oncology.2015;[Epub] CrossRef
Dosimetric Comparisons of Lung SBRT with Multiple Metastases by Two Advanced Planning Systems
Ye Zhang, Yie Chen, Jie Qiu, Jack Yang
International Journal of Medical Physics, Clinical Engineering and Radiation Oncology.2014; 03(04): 252. CrossRef
Frameless stereotactic body radiation therapy for multiple lung metastases
Qilin Li, Jinming Mu, Wendong Gu, Yuan Chen, Zhonghua Ning, Jianxue Jin, Honglei Pei
Journal of Applied Clinical Medical Physics.2014; 15(4): 105. CrossRef

13,673 View
72 Download
14 Crossref

Which Patients Might Benefit from Postmastectomy Radiotherapy in Breast Cancer Patients with T1-2 Tumor and 1-3 Axillary Lymph Nodes Metastasis?: Moonkyoo Kong, Seong Eon Hong; Cancer Res Treat. 2013;45(2):103-111. Published online June 30, 2013; DOI: https://doi.org/10.4143/crt.2013.45.2.103

Abstract PDF PubReader ePub

PURPOSE
This study compared the clinical outcomes of T1-2N1 breast cancer patients with and without postmastectomy radiotherapy (PMRT). Risk factors for loco-regional recurrence (LRR) were identified in order to define a subgroup of patients who might benefit from PMRT.
MATERIALS AND METHODS
Of 110 T1-2N1 breast cancer patients who underwent mastectomy from January 1994 through December 2009, 32 patients underwent PMRT and 78 patients did not. Treatment outcomes and risk factors for LRR were analyzed.
RESULTS
The 5- and 10-year LRR rates were both 6.2% in the PMRT group, and 10.4% and 14.6% in the no-PMRT group (p=0.336). In addition, no significant differences in distant metastasis-free survival (DMFS) or overall survival (OS) were observed between patients receiving and not receiving PMRT. In multivariate analysis, factors associated with higher LRR rates included grade 3 disease, extracapsular extension (ECE), and triple negative subtype. Patients who had one or more risk factors for LRR were defined as a high-risk patient group. In the high-risk group, both 5- and 10-year LRR rates for patients who underwent PMRT was 18.2%, and LRR rates of 21.4% at five years and 36.6% at 10 years were observed for patients who did not undergo PMRT (p=0.069).
CONCLUSION
PMRT in T1-2N1 breast cancer patients should be considered according to several prognostic factors in addition to T and N stage. Findings of our study indicated that PMRT did not improve LRR, DMFS, or OS in T1-2N1 breast cancer patients. However, in a subgroup of patients with grade 3 disease, ECE, or triple negative subtype, PMRT might be beneficial.

Citations

Citations to this article as recorded by

A Prognostic Risk Stratification Model to Identify Potential Population Benefiting From Postmastectomy Radiotherapy in T1–2 Breast Cancer With 1–3 Positive Axillary Lymph Nodes
Niuniu Hou, Juliang Zhang, Lu Yang, Ying Wu, Zhe Wang, Mingkun Zhang, Li Yang, Guangdong Hou, Jianfeng Wu, Yidi Wang, Bingyao Dong, Lili Guo, Mei Shi, Rui Ling
Frontiers in Oncology.2021;[Epub] CrossRef
SKIN AND SUBCUTANEOUS ADIPOSE TISSUE DAMAGE AFTER RADIATION THERAPY IN BREAST CANCER PATIENTS
D. Bazyka, O. Litvinenko, S. Bugaytsov, G. Shakhrai
Проблеми радіаційної медицини та радіобіології = Problems of Radiation Medicine and Radiobiology.2021; 26: 18. CrossRef
Multidisciplinary Management of the Axilla in Patients with cT1-T2 N0 Breast Cancer Undergoing Primary Mastectomy: Results from a Prospective Single-Institution Series
Samantha Grossmith, Anvy Nguyen, Jiani Hu, Jennifer K. Plichta, Faina Nakhlis, Linda Cutone, Laura Dominici, Mehra Golshan, Margaret Duggan, Katharine Carter, Esther Rhei, Thanh Barbie, Katherina Calvillo, Suniti Nimbkar, Jennifer Bellon, Julia Wong, Rina
Annals of Surgical Oncology.2018; 25(12): 3527. CrossRef
A prognostic score model to determine which breast cancer patients with 1-3 positive lymph nodes after modified radical mastectomy should receive radiotherapy
Dawei Chen, Haiyong Wang, Xinyu Song, Fang Shi, Li Kong, Jinming Yu
Oncotarget.2018; 9(1): 385. CrossRef
Postmastectomy radiation therapy for breast cancer patients with one to three positive lymph nodes: a propensity score matching analysis
Jiamao Lin, Cheng Li, Chenyue Zhang, Fang Shi, Haiyong Wang
Future Oncology.2017; 13(16): 1395. CrossRef
Predicting loco-regional recurrence risk in T1, T2 breast cancer with 1–3 positive axillary nodes postmastectomy: Development of a predictive nomogram
T Wadasadawala, S Kannan, S Gudi, A Rishi, A Budrukkar, V Parmar, T Shet, S Desai, S Gupta, R Badwe, R Sarin
Indian Journal of Cancer.2017; 54(1): 352. CrossRef
Comparison of Treatment Outcomes between Breast Conserving Surgery Followed by Radiotherapy and Mastectomy Alone in Patients with T1-2 Stage and 1-3 Axillary Lymph Nodes in the Era of Modern Adjuvant Systemic Treatments
Sang-Won Kim, Mison Chun, Sehwan Han, Yong Sik Jung, Jin Hyuk Choi, Seok Yun Kang, Hyunsoo Jang, Sunmi Jo, William B. Coleman
PLOS ONE.2016; 11(9): e0163748. CrossRef
Improvement of survival with postmastectomy radiotherapy in patients with 1-3 positive axillary lymph nodes: A systematic review and meta-analysis of the current literature
Hannah Headon, Abdul Kasem, Reham Almukbel, Kefah Mokbel
Molecular and Clinical Oncology.2016; 5(4): 429. CrossRef
ABCB1polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy
Hee‐Jun Kim, Seock‐Ah Im, Bhumsuk Keam, Hye Seon Ham, Kyung Hun Lee, Tae Yong Kim, Yu Jung Kim, Do‐Youn Oh, Jee Hyun Kim, Wonshik Han, In‐Jin Jang, Tae‐You Kim, In Ae Park, Dong Young Noh
Cancer Science.2015; 106(1): 86. CrossRef
Conservative Axillary Surgery in Breast Cancer Patients Undergoing Mastectomy: Long-Term Results
Michael S. Cowher, Stephen R. Grobmyer, Joanne Lyons, Colin O'Rourke, Deborah Baynes, Joseph P. Crowe
Journal of the American College of Surgeons.2014; 218(4): 819. CrossRef

10,424 View
64 Download
10 Crossref

Preoperative Concurrent Chemoradiotherapy for Locally Advanced Rectal Cancer: Treatment Outcomes and Analysis of Prognostic Factors: Moonkyoo Kong, Seong Eon Hong, Woo Suk Choi, Si-Young Kim, Jinhyun Choi; Cancer Res Treat. 2012;44(2):104-112. Published online June 30, 2012; DOI: https://doi.org/10.4143/crt.2012.44.2.104

Abstract PDF PubReader ePub

PURPOSE
This study was designed to investigate the long-term oncologic outcomes for locally advanced rectal cancer patients after treatment with preoperative concurrent chemoradiotherapy followed by total mesorectal excision, and to identify prognostic factors that affect survival and pathologic response.
MATERIALS AND METHODS
From June 1996 to June 2009, 135 patients with locally advanced rectal cancer were treated with preoperative concurrent chemoradiotherapy followed by total mesorectal excision at Kyung Hee University Hospital. Patient data was retrospectively collected and analyzed in order to determine the treatment outcomes and identify prognostic factors for survival.
RESULTS
The median follow-up time was 50 months (range, 4.5 to 157.8 months). After preoperative chemoradiotherapy, sphincter preservation surgery was accomplished in 67.4% of whole patients. A complete pathologic response was achieved in 16% of patients. The estimated 5- and 8-year overall survival, loco-regional recurrence-free survival, and distant metastasis-free survival rate for all patients was 82.7% and 75.7%, 76.8% and 71.9%, 67.9% and 63.3%, respectively. The estimated 5- and 8-year overall survival, loco-regional recurrence-free survival, and distant metastasis-free survival rate for pathologic complete responders was 100% and 100%, 100% and 88.9%, 95.5% and 95.5%, respectively. In the multivariate analysis, pathologic complete response was significantly associated with overall survival. The predictive factor for pathologic complete response was pretreatment clinical stage.
CONCLUSION
Preoperative chemoradiotherapy for locally advanced rectal cancer resulted in a high rate of overall survival, sphincter preservation, down-staging, and pathologic complete response. The patients achieving pathologic complete response had very favorable outcomes. Pathologic complete response was a significant prognostic factor for overall survival and the significant predictive factor for a pathologic complete response was pretreatment clinical stage.

Citations

Citations to this article as recorded by

Analysis of clinical and pathological prognostic factors of survival in rectal adenocarcinoma treated with preoperative radiochemotherapy
Sarhan Sydney Saad, Nora Forones, Gaspar Lopes Filho, Jaques Waisberg, Elesiario Caetano Júnior, Ricardo Artigiani-Neto, Delcio Matos
Acta Cirúrgica Brasileira.2025;[Epub] CrossRef
The optimal time interval between neoadjuvant chemoradiotherapy and surgery for patients with an unfavorable pathological response in locally advanced rectal cancer: a retrospective cohort study
Litao Wang, Jianyong Fan, Yaqi Guo, Shipeng Shang, Han Gao, Jianfei Xu, Peng Gao, Enrui Liu
Frontiers in Oncology.2025;[Epub] CrossRef
Characteristics of Patients Presented With Metastases During or After Completion of Chemoradiation Therapy for Locally Advanced Rectal Cancer: A Case Series
Radwan Torky, Mohammed Alessa, Ho Seung Kim, Ahmed Sakr, Eman Zakarneh, Fozan Sauri, Heejin Bae, Nam Kyu Kim
Annals of Coloproctology.2021; 37(3): 186. CrossRef
A prospective analysis of the diagnostic accuracy of 3 T MRI, CT and endoscopic ultrasound for preoperative T staging of potentially resectable esophageal cancer
Jia Guo, Zhaoqi Wang, Jianjun Qin, Hongkai Zhang, Wentao Liu, Yan Zhao, Yanan Lu, Xu Yan, Zhongxian Zhang, Ting Zhang, Shouning Zhang, Nickel Marcel Dominik, Ihab R. Kamel, Hailiang Li, Jinrong Qu
Cancer Imaging.2020;[Epub] CrossRef
Sustaining Blood Lymphocyte Count during Preoperative Chemoradiotherapy as a Predictive Marker for Pathologic Complete Response in Locally Advanced Rectal Cancer
Jaesung Heo, Mison Chun, O Kyu Noh, Young-Taek Oh, Kwang Wook Suh, Jun Eun Park, Oyeon Cho
Cancer Research and Treatment.2016; 48(1): 232. CrossRef
Differential effects of patient-related factors on the outcome of radiation therapy for rectal cancer
Ikuko Kato, Gregory Dyson, Michael Snyder, Hyeong-Reh Kim, Richard K. Severson
Journal of Radiation Oncology.2016; 5(3): 279. CrossRef
JOURNAL CLUB: Preoperative MRI Evaluation of Primary Rectal Cancer: Intrasubject Comparison With and Without Rectal Distention
Feng Ye, Hongmei Zhang, Xiao Liang, Han Ouyang, Xinming Zhao, Chunwu Zhou
American Journal of Roentgenology.2016; 207(1): 32. CrossRef
Utility of high resolution MRI for pre-operative staging of rectal carcinoma, involvement of the mesorectal fascia and circumferential resection margin
Tamir A. Hassan, Hossam M. Abdel-Rahman, Hala Yehia Ali
The Egyptian Journal of Radiology and Nuclear Medicine.2016; 47(4): 1243. CrossRef
Severe weight loss during preoperative chemoradiotherapy compromises survival outcome for patients with locally advanced rectal cancer
Junzhong Lin, Jianhong Peng, Aiham Qdaisat, Liren Li, Gong Chen, Zhenhai Lu, Xiaojun Wu, Yuanhong Gao, Zhifan Zeng, Peirong Ding, Zhizhong Pan
Journal of Cancer Research and Clinical Oncology.2016; 142(12): 2551. CrossRef
Complete radiotherapy response in rectal cancer: A review of the evidence
Daniel G Couch
World Journal of Gastroenterology.2016; 22(2): 467. CrossRef
The Value of High-Resolution MRI Technique in Patients with Rectal Carcinoma: Pre-Operative Assessment of Mesorectal Fascia Involvement, Circumferential Resection Margin and Local Staging
Samah Kohla
Polish Journal of Radiology.2015; 80: 115. CrossRef
Is complete mesocolic excision with central vascular ligation safe and effective in the surgical treatment of right-sided colon cancers? A prospective study
Gennaro Galizia, Eva Lieto, Ferdinando De Vita, Francesca Ferraraccio, Anna Zamboli, Andrea Mabilia, Annamaria Auricchio, Paolo Castellano, Vincenzo Napolitano, Michele Orditura
International Journal of Colorectal Disease.2014; 29(1): 89. CrossRef
Accuracy of High-Resolution MRI with Lumen Distention in Rectal Cancer Staging and Circumferential Margin Involvement Prediction
Elsa Iannicelli, Sara Di Renzo, Mario Ferri, Emanuela Pilozzi, Marco Di Girolamo, Alessandra Sapori, Vincenzo Ziparo, Vincenzo David
Korean Journal of Radiology.2014; 15(1): 37. CrossRef
EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum
Cornelis J.H. van de Velde, Petra G. Boelens, Josep M. Borras, Jan-Willem Coebergh, Andres Cervantes, Lennart Blomqvist, Regina G.H. Beets-Tan, Colette B.M. van den Broek, Gina Brown, Eric Van Cutsem, Eloy Espin, Karin Haustermans, Bengt Glimelius, Lene H
European Journal of Cancer.2014; 50(1): 1.e1. CrossRef
Eine intensivierte Chemotherapie erhöht die Effektivität nicht, oder doch?
Gunther Klautke
Info Onkologie.2014; 17(6): 17. CrossRef
Sphincter preservation in distal CT2N0 rectal cancer after preoperative chemoradiotherapy
Nir Wasserberg, Yulia Kundel, Ofer Purim, Andrei Keidar, Hanoch Kashtan, Eran Sadot, Eyal Fenig, Baruch Brenner
Radiation Oncology.2014;[Epub] CrossRef
Metformin use and improved response to therapy in rectal cancer
Heath D. Skinner, Christopher H. Crane, Christopher R. Garrett, Cathy Eng, George J. Chang, John M. Skibber, Miguel A. Rodriguez‐Bigas, Patrick Kelly, Vlad C. Sandulache, Marc E. Delclos, Sunil Krishnan, Prajnan Das
Cancer Medicine.2013; 2(1): 99. CrossRef

12,854 View
54 Download
17 Crossref

Clinical Implications of VEGF and p53 Expression in Squamous Cell Carcinoma of the Cervix Treated with Radiation Therapy: Jin Oh Kang, Seong Eon Hong, Dong Wook Kang; Cancer Res Treat. 2003;35(5):440-444. Published online October 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.5.440

Abstract PDF

PURPOSE
The present study was designed to analyze the relationship between vascular endothelial growth factor (VEGF) and p53, and their impact on clinical outcome in squamous cell carcinoma of the cervix treated with radiation therapy. MATERIALS AND METHODS: This immunohistochemical study involved 23 patients with available paraffin blocks among 46 patients who were treated during the period from 1994 to 1997 in Eulji University Hospital in Korea. Anti-VEGF mouse monoclonal antibody and DO-7 anti- p53 mouse monoclonal antibody were used as the primary antibodies. Antibody binding was detected with a LSAB kit. Staining was defined as positive for VEGF and p53, when more than 10% and 5% of the tumor cells were stained out of 500 cells counted, respectively. RESULTS: FIGO stage (p=0.05) and tumor size (p=0.04) were significant prognostic factors for survival. p53 expression was present in 17 (77%) cases. There was no significant relationship between p53 staining and the clinicopathologic factors, such as FIGO stage (p=0.98), tumor size (p=0.43), lymph node status (p=0.82), parametrial invasion (p=0.96), and age (p=0.18). The five year survival rates according to the p53 expression status were 80% for the p53 negative group and 66% for the p53 positive group (p=0.58). Positive VEGF expression was observed in 11 (47%) of the total of 23 patients. Statistical evaluation of VEGF expression according to stage (p=0.36), tumor size(p=0.11), lymph node status (p=0.82), parametrial invasion (p=0.49), and age (p=0.55) revealed no significant difference in any of these parameters. The five year survival rates according to the VEGF expression status were 89% for the VEGF negative group and 41% for the VEGF positive group (p=0.07). CONCLUSION: We suggest that VEGF expression may have an effect on the prognosis of cervix cancer patients treated with radiation therapy, and further evaluation with a large sample size is warranted.

Citations

Citations to this article as recorded by

Research advances in signaling pathways related to the malignant progression of HSIL to invasive cervical cancer: A review
Huifang Wang, Chang Liu, Keer Jin, Xiang Li, Jiaxin Zheng, Danbo Wang
Biomedicine & Pharmacotherapy.2024; 180: 117483. CrossRef

3,701 View
17 Download
1 Crossref

Neoadjuvant Chemotherapy with 5-Fluorouracil and Cisplatin for Locally Advanced Head and Neck Cancer: Ji Hoon Park, Hwan Suk Choi, Jeong Hee Kim, Si Young Kim, Hwi Joong Yoon, Kyung Sam Cho, Seong Eon Hong, Dong Mok Ryu, Hoe Young Ahn; J Korean Cancer Assoc. 1995;27(6):990-1002.

Abstract PDF: Background
The prognosis for patients with locally advanced head and neck cancer remains poor. In recent years, attempts at improving the poor survival rates have frquently focused on the initial use of chemotherapy followed by subsequent standard local therapy with surgery and radiation. Methods: Twenty-seven patients with previously untreated, locally advanced (stage III or IV) head and neck cancer were treated with 2 or 3 cycles of combination chemotherapy consisting of 5-fluorouracil infusion and cisplatin followed by operation or radiotherapy between January,1988 and March,1994. Results: 1) After the neoadjuvant FP chemotherapy, sixteen of 27 patients(59.2%) demonstrated an objective response, with one(3.7%) achieving a complete clinical response(CR) and fifteen(55.5%) a partial response(PR). After the definitive local therapy(DLT:operation or radiation therapy), 12(44.4%) patients had a CR and 12(44.4%) achieved PR, respectively with 88.8% overall response rates. 2) Twelve patients received operation and 15 patients received radiotherapy after the neoadjuvant chemotherapy. Among 12 patients who received operation, seven(58%) patients achieved curative resection with surgery and five(33%) patients a complete remission, seven patients(46.7%) a partial remission with radiotherapy. 3) The overall median survival of total 27 patients was 31 months. The median survival of the responders (median:54 months) to FP chemotherapy was not significantly prolonged compared with nonresponders(median:23 months). 4) Time to disease progression of the responders to definite local therapy was 19 months. 5) Leukopenia and thrombocytopenia were observed in 48%(grade I-III) and l0%(grade I- II) respectively. Nausea and vomiting were observed in all patients, but easily controlled. Alopecia, diarrhea, stomatitis and nephrotoxicity were observed infrequently. There were no treatment related fatalities. Conclusion: Neoadjuvant FP chemotherapy in patients with locally advanced head and neck cancer was tolerable, but did not improve the response rate and overall survival compared with previous other reports. The phase III randomized controlled prospective studies are warranted for the verification of this study

3,161 View
17 Download

First
Prev
Page of 1
Next
Last

Search